BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics
January 26, 2026
BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. to strengthen its leadership in hereditary angioedema (HAE) and support long-term growth. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor (Phase 3), and also brings Astria’s early-stage atopic dermatitis program STAR0310 (for strategic alternatives).
- Buyers
- BioCryst Pharmaceuticals, Inc.
- Targets
- Astria Therapeutics, Inc.
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals
September 1, 2026
Pharmaceuticals
Vertex Pharmaceuticals Incorporated completed its acquisition of Crinetics Pharmaceuticals, Inc. on September 1, 2026, in a transaction valued at approximately $10 billion in equity value. The acquisition adds PALSONIFY, atumelnant and other pipeline programs, establishing rare endocrine diseases as a new growth area for Vertex.
-
BioMarin Acquires Alesta Therapeutics
August 18, 2026
Biotechnology
BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.
-
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B
July 5, 2026
Pharmaceuticals
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for total equity value of about $10 billion ($8.8 billion net of estimated cash acquired). The deal—priced at $85 per share—was announced as a definitive agreement and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.
-
Axsome Therapeutics Acquires Baergic Bio to Secure Global Rights to AZD7325
November 8, 2025
Pharmaceuticals
Axsome Therapeutics acquired a 100% equity interest in Baergic Bio (a subsidiary of Avenue Therapeutics) and amended Baergic Bio's license with AstraZeneca to obtain exclusive global rights to AZD7325, an early‑stage selective GABAA α2,3 receptor modulator for epilepsy. The deal includes a $0.3 million upfront payment to Baergic Bio shareholders and potential development, regulatory, sales‑based milestones and tiered royalties to Avenue Therapeutics and AstraZeneca as described in the purchase and amended license agreements.
-
biote Corp Acquires Asteria Health
January 17, 2024
Healthcare Services
biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.
-
Aeglea BioTherapeutics Acquires Spyre Therapeutics
June 22, 2023
Biotechnology
Aeglea BioTherapeutics completed a stock-for-stock acquisition of Spyre Therapeutics, a privately held biotechnology company advancing antibody therapeutics for inflammatory bowel disease (IBD). Concurrent with the acquisition Aeglea announced a $210 million PIPE led by Fairmount Funds to advance Spyre’s pipeline (lead programs SPY001 and SPY002) into clinical studies and fund operations into 2026.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.